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ABSTRACT
Introduction: Pseudobulbar affect (PBA) is 
a neurologic syndrome of emotional affect 
disinhibition, characterized by uncontrollable, 
exaggerated, and often inappropriate emotional 
outbursts, which may cause severe distress, 
embarrassment, and social dysfunction. However, 
the US prevalence of PBA remains unknown. 
Methods: An online survey was conducted 
primarily to estimate the US prevalence of 
PBA in patients with the six most commonly 
associated conditions: Alzheimer’s disease, 
amyotrophic lateral sclerosis, multiple sclerosis, 
Parkinson’s disease, stroke, and traumatic 
brain injury. Invitations to participate were 
randomly sent online to adults (aged ≥18 years) 
registered in the Harris Poll Online Panel who 
were patients or belonged to a household with a 
patient diagnosed with one of the six conditions 
(identified through previous screening by Harris 
Interactive). Participants were screened for PBA 
using the Pathological Laughing and Crying 
Scale (PLACS) and the Center for Neurologic 
Study-Lability Scale (CNS-LS). PBA estimates 
were made using a cut-off score of ≥13 on the 
PLACS and two different cut-off thresholds on 
the CNS-LS, a lower one of ≥13 and a more 
rigorous one of ≥21. Existing US prevalence 
data for the six underlying conditions were used 
to estimate US prevalence of PBA. Results: Of 
38,000 individuals invited to participate, 8876 
responded (23%) and 2318 (26%) completed the 
questionnaire. Mean prevalence of PBA across 
all six conditions was 10.1%, 9.4%, and 37.5% 
with the PLACS ≥13, CNS-LS ≥21, and CNS-LS 
≥13 thresholds, respectively. Using disease 
population estimates from government agencies 
and professional organizations, the estimated 
US population with PBA ranged from 1.8 to 7.1 
million. Among patients who discussed their 
laughing and/or crying episodes with a physician, 
41% were diagnosed, and about half received a 
medication for their episodes. Conclusions: The 
overall prevalence of PBA was estimated to be 
about 10% across these commonly associated 
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underlying neurological conditions and appears 
to be under-recognized.
Keywords: Alzheimer’s disease; amyotrophic 
lateral sclerosis; diagnosis; multiple sclerosis; 
Parkinson’s disease; prevalence; pseudobulbar 
affect; stroke; traumatic brain injury; treatment 
INTRODUCTION
Pseudobulbar affect (PBA) is a neurologic 
syndrome of emotional affect disinhibition, 
characterized by frequent, uncontrollable 
emotional outbursts of crying and/or laughing 
that are usually exaggerated and inappropriate to 
the stimulus, and may be mood incongruent.1-3 
Some patients may also display outbursts of anger 
or frustration.4 PBA occurs primarily in patients 
with neurologic conditions, stroke, or traumatic 
brain injury (TBI) and has been reported in 
patients with brain injury from numerous other 
causes, such as tumors, aneurysms, and herpes 
encephalitis.3,5 Although its etiology is unclear, 
PBA is thought to be caused by the presence of 
brain lesions interfering with neural circuits and 
neurotransmitters that regulate voluntary and 
perhaps over-learned involuntary emotional 
expression.2,3
Clinical syndromes of abnormal emotional 
expression in patients with brain lesions or 
injury have been noted since at least the late 
19th century and defined with varying terms and 
descriptions, including pathological laughter and 
crying (PLC), involuntary emotional expression 
disorder, and emotional lability.1,6 Clinical 
case and study data have shown that PBA may 
cause severe distress, embarrassment, and social 
disability among patients.3,7-10 In addition, studies 
have shown that patients with PBA or similar 
syndromes experience an increased incidence 
of depression,11 impairments in executive 
function12 and sexual function,13 and ability to 
perform activities of daily living14 compared with 
patients with the same underlying neurological 
disorder but without PBA. 
However, the total prevalence of PBA in the 
USA remains unclear. Prevalence estimates for 
PBA in each of the six most commonly associated 
conditions – amyotrophic lateral sclerosis (ALS), 
Alzheimer’s disease (AD)/dementia, multiple 
sclerosis (MS), Parkinson’s disease (PD), stroke, 
and TBI – have differed considerably within each 
population1,3 (Figure 15,10,11,15-32). This variability 
is probably due to differences in the populations 
studied and in the criteria and methods used for 
identifying PBA.1,3 Yet, no previous study has 
sought to estimate the prevalence of PBA across 
different disorders using similar criteria and 
methods of identification. 
In addition, several researchers have observed 























Figure 1. Ranges of estimated prevalence for PBA and 
similar syndromes, such as emotional lability as variously 
defined and identified in published reports are indicated 
by the vertical gray arrows.5,10,11,15-32 Prevalence rates 
determined in the present study with PLACS≥13 and 
CNS-LS≥13 are indicated by the transverse plot points. 
The prevalence rates determined with CNS-LS≥21 
in the present study were very similar to those for 
PLACS≥13, and are not shown here to enhance visual 
clarity. AD=Alzheimer’s disease; ALS=amyotrophic lateral 
sclerosis; MS=multiple sclerosis; PD=Parkinson’s disease; 
TBI=traumatic brain injury.
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misdiagnosed, and under-treated, although there 
are few data to quantify these observations.1,3,8,33
We conducted an online survey among patients 
in the USA with six underlying conditions 
commonly associated with PBA – ALS, MS, 
stroke, AD/dementia, TBI, and PD – in order to 
prospectively estimate the overall prevalence 
of PBA and quantify the extent to which PBA 
is diagnosed and treated. Secondary goals were 
to investigate patterns of physician recognition, 
diagnosis, and treatment of PBA.
MATERIALS AND METHODS
Survey Overview 
This stratified sample survey was designed and 
directed by the authors. Avanir Pharmaceuticals 
commissioned the study, which was conducted 
by Harris Interactive® (HI), a market research firm 
specializing in public opinion and consumer 
surveys (http://www.harrisinteractive.com). 
Both patients with PBA and caregivers were 
surveyed to ensure participation of more severely 
incapacitated patients.
Study Sample 
The study sample was drawn from a nationally 
representative sample of more than 6 million US 
adults (aged 18 years and over), registered in the 
Harris Poll Online (HPOL). The HPOL includes 
1.5 million subjects who have been screened 
by HI via a checklist for presence of chronic 
illnesses. To recruit patients with ALS, AD, MS, 
PD and stroke, HPOL panel members previously 
identified by HI as either having one of the 
above conditions, or being a primary caregiver 
for a household member with the condition 
were sent online invitations inviting them to 
participate in a survey about their “thoughts on 
and experiences with some important healthcare 
related topics.” The online survey was fielded 
between September 20 and October 7, 2005. 
As TBI is not part of the HI Chronic Illness 
Screener instrument, these patients were 
identified by sending survey invitations to panel 
members with chronic headaches, posttraumatic 
stress disorder (PTSD), or general disability. The 
survey asked these members if they had been 
diagnosed by a physician or other healthcare 
professional with TBI, defined as a head injury 
requiring hospitalization, which resulted from 
being knocked unconscious, having a skull 
fracture, or suffering other brain injury. The 
TBI patients in this sample thus represented a 
subset of relatively severe cases, as US data show 
that only about 16% of TBI survivors annually 
are hospitalized for their injury.34 In addition, 
invitations were sent to a randomized national 
sample from the general HPOL to enhance the 
representativeness of the sample. Recruitment 
quotas were set for each underlying condition 
in order to have a large enough sample of each 
disease state for analysis (Table 1). 
Study Measures
To identify PBA, participants were asked to 
complete the Pathological Laughing and Crying 
Scale (PLACS),31 and the Center for Neurologic 
Study-Lability Scale (CNS-LS),4,35 which includes 
an auxiliary subscale for episodes of anger/
frustration. Patients and caregivers were asked 
the same questions, with caregivers answering 
based on their observations of the patient. 
PLACS 
The PLACS is an interviewer-rated instrument 
that measures the severity of PBA symptoms, 
and has been validated in stroke patients.31 
Eight items of the scale relate to laughing and 
eight to crying. The scale begins with two 
screening questions asking if the respondent 
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Table 1. Estimated prevalence of PBA within and across the six most commonly associated neurologic conditions. 
Population ALS AD/dementia MS PD Stroke TBI TOTAL
Desired sample quota 225 500 500 500 500 ≥250* 2475
Invitations mailed 4343 5124 6723 5721 7013 9013† 37937
Survey total, n  40 499 504 449 500 326 2318
Patients/caregivers, n 25/15 49/450 418/86 254/195 415/85 273/53 1434/884
Patients/caregivers, % 63/37 10/90 83/17 57/43 83/17 84/16 62/38
Proportion of patients with PBA per scale/threshold criteria
PLACS≥13, % 32.5 9.2 9.8 5.0 4.7 17.4 10.1
CNS-LS≥21, % 27.5 9.6 9.8 3.6 4.3 15.5  9.4
CNS-LS≥13, % 50.0 38.5 46.2 24.0 27.6 48.2 37.5
Margin of error at 95% 
confidence, % 15.5 4.4 4.4 4.6 4.4 5.4 2.0
Estimated US prevalence of underlying conditions
US prevalence: Source 1‡ 30,000 6,800,000 400,000 1,000,000 5,400,000 5,300,000 18,930,000
  (4,000,000 AD)  
US prevalence: Source 2§ 17,928|| 747,000 179,280¶ 597,600 1,942,200# 2,390,400  5,874,408
Estimated US prevalence of PBA 
PLACS≥13:  Source 1: 9750 625,600 39,200 50,000 253,800 922,200 1,911,930
 Source 2: 5827 68,724 17,569 29,880  91,283 415,930 593,315
CNS-LS≥21:    Source 1: 8250 652,800 39,200 36,000 232,200 821,500 1,779,420
 Source 2: 4930 71,712 17,569 21,514  83,515 370,512 552,194
CNS-LS≥13:    Source 1: 15,000 2,618,000 184,800 240,000 1,490,400 2,554,600 7,098,750
 Source 2:  8964 287,595 82,827 143,424 536,047 1,152,173 2,202,903
*As TBI is not included as part of the Harris Chronic Illness Panel, the potential sample pool was unknown and thus 
quota limits for TBI were difficult to anticipate; therefore, quota limits for TBI were set at 250 to 500. 
†As TBI is not included as part of the Harris Chronic Illness Panel, TBI was identified by sending survey invitations to panel 
members with chronic headaches, posttraumatic stress disorder (PTSD), or general disability, and inquiring whether these 
members had been diagnosed by a physician or other healthcare professional with TBI, defined as a head injury requiring 
hospitalization, which resulted from being knocked unconscious, having a skull fracture, or suffering other brain injury. 
Therefore, a greater number of invitations were sent to these groups in order to identify a sufficient number of patients with TBI. 
‡Source 1: Prevalence was derived from the following professional and government organization Web sites: 
1. ALS: The ALS Association.38 
2. AD/dementia: National Institute of Neurological Disorders and Stroke (NINDS).39 
3. MS: National MS Society.40 
4. PD: Parkinson’s Disease Foundation.41 
5. Stroke: American Stroke Association.42 
6. TBI: Centers for Disease Control (CDC) and National Center for Injury Prevention and Control (NCIPC) estimate of 
Americans who currently have a long-term or lifelong need for help to perform activities of daily living as a result of a TBI.43 
§Source 2: Prevalence was calculated from approximate point prevalence rates per 100,000 population (all ages) 
provided by Wallin and Kurtzke, 200444 multiplied by 2988, ie, the approximate total current USA population divided 
by 100,000. The number used for the total USA resident population (298,755,510) was derived from the Population 
Division of the United States Census Bureau.45 
||Motor neuron disease.
¶Rate for high-risk areas.
#Acute cerebrovascular disease and subarachnoid hemorrhage.
AD=Alzheimer’s disease; CNS-LS=Center for Neurologic Study-Lability Scale; MS=multiple sclerosis; PBA=pseudobulbar 
affect; PD=Parkinson’s disease; PLACS=Pathological Laughing and Crying Scale; TBI= traumatic brain injury. 
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has experienced laughing or crying episodes; 
if either question or both are answered “rarely 
or no,” the following questions related to 
laughing or crying, or the rest of the scale, is 
not administered. Each item/symptom is scored 
for severity on a scale of 0 to 3 points (0=rarely 
or not at all, 3=frequently), and then totaled 
to obtain an overall score. In stroke patients, 
a PLACS cut-off total score of ≥13 (PLACS≥13) 
has been shown to distinguish individuals with 
PBA, with a sensitivity for clinically diagnosed 
PBA of 0.88, a specificity of 0.96, and a positive 
predictive value of 0.83 (n=67).31 The PLACS has 
not been validated in other populations. For 
purposes of this survey, the PLACS questions 
were revised to allow for self-administration. 
CNS-LS and Auxiliary Subscale 
The CNS-LS is a self-report measure of PBA 
that has been validated in both ALS4 and MS35 
patients. The CNS-LS consists of a subscale for 
laughter (four items) and one for tearfulness 
(three items), with each item scored on a five-
point scale (1=applies never, 5=applies most of 
the time). In ALS patients (n=99), a cut-off score 
of 13 on the CNS-LS was found to successfully 
predict neurologists’ diagnoses of PBA for 82% of 
patients, with a sensitivity of 0.84 and a specificity 
of 0.81; the CNS-LS also showed good test-
retest reliability (0.88) and internal consistency 
(Cronbach’s α coefficient=0.87).4 In MS patients 
(n=90), a CNS-LS cut-off score of 13 correctly 
predicted 78% of physicians’ diagnoses regarding 
PBA, with a sensitivity of 0.96 and a specificity of 
0.55, while a cut-off score of 17 correctly predicted 
89% of physicians’ diagnoses, with a sensitivity of 
0.94 and specificity of 0.83.35 For this survey, a 
CNS-LS cut-off score of ≥13 (CNS-LS≥13) was used 
as previously validated, and a more conservative 
cutoff of ≥21 (CNS-LS≥21) was also used, based on 
mean CNS-LS baseline scores from clinical trials 
in patients with MS or ALS and PBA.33,36
An eight-item auxiliary subscale of the CNS-LS 
measures episodes of labile anger, frustration, 
and impatience that may have a syndromal 
association with laughing and crying episodes.4 
When combined with the seven items of the 
CNS-LS in ALS patients, the resulting 15-item 
scale showed an internal consistency of 0.92 
and test-retest reliability of 0.88.4 A score of ≥27 
on the combined scale predicted physicians’ 
diagnoses regarding PBA with a sensitivity of 
0.74 and a specificity of 0.80.4 A cut-off score 
of ≥15 on the auxiliary scale to identify patients 
with labile anger, frustration, and impatience, 
associated with or independent of crying/
laughter, was used in this trial based on the 
reported auxiliary scale scores of patients with 
and without PBA4 and additional clinical trial 
experience with this subscale communicated by 
R.A. Smith in a telephone conversation (March 
2006).37
Prevalence Estimates 
Prevalence estimates for each of the six 
underlying neurological conditions were derived 
from two sources: professional and government 
organizations that serve as resources for US 
disease-prevalence data (Table 1, Source 138-43), 
and a standard neuro-epidemiological review 
textbook (Table 1, Source 244,45).44,46,47 These data 
were found to be divergent, indicating lack of 
consensus on these statistics, with estimates 
generated by professional and government 
organizations being generally higher than those 
from published research reports cited in the 
textbook. Therefore, it was deemed prudent and 
appropriate to present both sets of data. The 
percentage frequency of PBA for each condition 
according to the PLACS and CNS-LS scores was 
multiplied by the prevalence of each disease and 
summed to derive a total estimated prevalence 
of PBA in the USA. 
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Assessment of PBA Diagnosis and Treatment 
Patterns
With regard to management of PBA, respondents 
were asked what kind of physician is mostly 
responsible for their care; if they had discussed 
the symptoms with that physician; if a diagnosis 
had been given for sudden crying or laughing 
or both; and if the physician had prescribed 
medication for recent episodes of crying/
laughing or anger/frustration. 
Statistical Analysis
Weighting for Demographic Variables and 
Proportionality 
To adjust for potential bias due to nonresponse 
and to ensure that the sample was representative 
of the US adult population in each disease 
group, patient data for four of the six underlying 
conditions were weighted.48 Weighting factors 
were applied to match the age and gender 
proportions of respondents with each disease 
to national figures provided by the National 
Center for Health Statistics/National Health and 
Nutrition Examination Survey49 and the National 
Center for Injury Prevention and Control/
Centers for Disease Control and Prevention.50 
For example, because there was a low response 
rate among young male TBI patients, who make 
up a substantial portion of this population, 
responses from young male TBI patients were 
inflated to reflect their true proportion among 
TBI patients.
Demographic weighting targets were applied 
only to patients, as caregivers did not provide 
age and gender data for their patients. As 90% of 
AD respondents were caregivers, the number of 
AD patient respondents was too small to weight. 
Similarly, the number of ALS patient respondents 
was too small to weight, due to the low incidence 
of the condition. “Unweighted” respondents 
were assigned a demographic weight of 1. For 
prevalence estimates, a proportional weight was 
assigned to each respondent (in addition to the 
demographic weights for each condition, where 
applicable) based on the proportion of their 
condition among all six conditions combined 
(Table 1, Source 138-43). For uniformity, all 
sample sizes are reported herein as unweighted 
numbers; however, all percentages calculated 
from participant responses are reported with 
weighting factors applied.
Margin of Sampling Error 
With probability samples the size of this 
survey sample (n=2318), there is 95% certainty 
that the results have a sampling error of ±2%. 
Although the online sample does not meet the 
strict criteria of a probability sample, a similar 
margin of sampling error is expected here. 
Analysis of individual neurological conditions 
yields a larger sampling error due to smaller 
sample sizes (Table 1). The margin of error at the 
95% confidence interval (CI) is approximately 
4% to 6% for the various conditions, with the 
exception of the smaller ALS sample (n=40), for 
which the margin of error is about 16%. 
Backfill of Missing Data 
The original survey was missing a question 
from the PLACS scale regarding the frequency 
of laughing and/or crying episodes. Therefore, 
a recontact survey was conducted among 
respondents who were asked the PLACS 
questions, of whom 86% completed the missing 
questions. To backfill missing responses, the 
multiple imputation capabilities in the Statistical 
Analysis System 9.0 were used to estimate 
replacement values.51 The Markov Chain Monte 
Carlo method in SAS PROC MI was used to create 
a single “imputation” for each missing item. Each 
imputed value was constrained to an integer 
value in the range of the original data (0-3). 
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RESULTS
Survey Population
A random sample of approximately 38,000 
subjects (n=37,937) of the HPOL database who 
had previously been identified as having ALS, 
AD, MS, PD, stroke, or symptoms suggestive of 
TBI were invited to participate. The average time 
to complete the online survey was 9 minutes. 
Of the 8876 (23.4%) respondents, 6086 (68.6%) 
were ineligible to participate due to non-US 
residence, respondent age (<18 years), or not 
having been diagnosed with one of the six 
underlying conditions of interest. Of the 2790 
eligible respondents, 2318 (83.1%) completed 
the questionnaire and were used in the final data 
set. An additional 179 (6.4%) did not finish the 
survey, and 293 (10.5%) were eliminated because 
the quota for their disease state had already been 
met (Table 1). The relative proportions of patients 
and caregivers in each group also varied widely, 
with caregivers comprising a high of 90% of 
respondents in the AD group, and a low of 17% 
in both the MS and stroke groups (Table 1). 
PBA Prevalence 
The CNS-LS scale with a cut-off score of ≥13 
yielded larger estimates of PBA prevalence 
within and across the disease groups, compared 
with the higher CNS-LS threshold of 21 points 
(CNS-LS≥21) and the PLACS cutoff of ≥13, which 
produced similar rates (Table 1). The mean 
prevalence estimate of PBA across all six diseases 
was 10.1% as identified by a PLACS≥13 score; 
9.4% with the CNS-LS≥21 score; and 37.5% with 
a CNS-LS≥13 cutoff. PBA prevalence estimates 
differed substantially among the six neurologic 
conditions evaluated, being highest in ALS and 
lowest in PD, regardless of the criteria used 
(Table 1). 
US Population Estimates 
Application of the PLACS≥13 and CNS-LS≥21 
estimates for PBA to prevalence estimates from 
the US government and from professional 
organizations for the six underlying conditions 
yielded similar prevalence estimates for 
PBA, while the CNS-LS≥13 threshold derived 
markedly higher estimates (Table 1). The 
estimates of total US prevalence of PBA based on 
government data (Source 138-43) were 1.9 million 
with PLACS≥13, 1.8 million with CNS-LS≥21, 
and 7.1 million with the CNS-LS≥13 threshold 
(Table 1). Using the lower prevalence data from 
the neuro-epidemiological review by Wallin and 
Kurtzke44 (Source 244,45), the estimates for total 
US prevalence of PBA were 0.6 million with 
PLACS≥13, 0.55 million with CNS-LS≥21, and 
2.2 million with CNS-LS≥13 (Table 1). 
Episodic Anger and Frustration Related to 
PBA 
Among all respondents, 58.7% scored ≥15 on 
the anger/frustration subscale of the CNS-LS, 
ranging among disease groups from a high of 
74.1% in those with AD to a low of 40.3% in the 
stroke group. Anger/frustration and laughing/
crying episodes were often coexistent; a greater 
percentage (25.3%) of patients with scores 
of ≥15 for anger/frustration also experienced 
inappropriate laughing/crying episodes 
compared with the overall sample (16%). 
Moreover, most patients exceeding PLACS and 
CNS-LS threshold scores for laughing/crying 
also reported anger/frustration episodes; 90.5% 
of patients with a PLACS score ≥13, 95.8% of 
patients with a CNS-LS score ≥21, and 88.3% of 
patients with a CNS-LS score ≥13 also had a score 
of ≥15 for anger/frustration. However, 41.3% 
of respondents who scored <13 in the CNS-LS 
scored ≥15 on the anger/frustration subscale, 
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suggesting that anger/frustration episodes 
may be a primary manifestation of emotional 
lability in many patients, and that including 
these episodes in the definition of PBA would 
affect prevalence estimates. Caregivers reported 
a markedly higher percentage of ≥15 anger/
frustration scores (72.7%) than did patients 
(47.6%). 
Diagnosis of PBA 
Of the 937 respondents who screened positive 
for PBA using CNS-LS≥13 and/or reported 
sudden episodes of crying and/or laughter, 
637 (73.6% weighted) said they had discussed 
their episodes of laughing and/or crying with 
a physician. Of the respondents who discussed 
their sudden crying/laughter with a physician, 
41% were given a diagnosis for the episodes 
(Table 2), which, as reported by the patients/
caregivers, was most often depression, or that 
the symptoms were related to their underlying 
illness; however, no respondents reported a 
diagnosis of PBA, PLC, or related terminology 
(Figure 2). 
Table 2. Diagnosis and treatment in patients who discussed their sudden crying and/or laughing episodes with a physician.
 Total*  ALS AD MS PD Stroke TBI
Given diagnosis? (n=637) (n=21) (n=171) (n=121) (n=97) (n=96) (n=131)
Yes, % 41 38 37 29 23 35 51
No, % 59 62 63 71 77 65 49
Requested treatment? Total*†  ALS AD MS PD Stroke TBI
 (n=671) (n=21) (n=186) (n=129) (n=99) (n=103) (n=133)
Yes, % 46 52 39 37 39 45 55
No, % 54 48 61 63 61 55 45
Prescribed medication? Total*†  ALS AD MS PD Stroke TBI
 (n=671) (n=21) (n=186) (n=129) (n=99) (n=103) (n=133)
Yes, % 52 43 51 42 36 50 56
No, % 48 57 49 58 64 50 44
*Total weighted proportionally among all six conditions based on their prevalence in the general population.
†Includes patients who discussed laughing/crying and/or anger/frustration episodes with a physician. 





Just part of condition 28%
Bipolar/mood disorder 13%






Figure 2. Diagnoses received across all disease groups 
by patients who discussed their laughing and/or crying 
episodes with a physician and were given a diagnosis 
(total n=227). *Includes various personality disorders, 
psychotic disorders, “stress.”
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Treatment of PBA 
Of patients who discussed their episodes of 
involuntary crying and/or laughing with their 
physician (total n=671), 46% requested treatment 
and 52% were prescribed a medication (Table 
2), including 85% of the patients who requested 
treatment and 24% of those who did not 
specifically request treatment. Among patients 
who did not request treatment, the most common 
reasons given were that “the recent episodes of 
crying and/or laughter do not significantly impair 
my quality of life” and “I have other conditions 
and/or health issues that I consider to be more 
important than my recent episodes of crying 
and/or laughter.” Of all survey respondents (total 
n=2318), 40% were taking medications that 
have been reported to be potentially effective 
in reducing PBA symptoms, such as tricyclic 
antidepressants (8%), other antidepressants (31%), 
or antipsychotics (13%). Among patients with a 
score of ≥15 on the anger/frustration subscale, 
53% reported receiving these medications. Among 
patients with a CNS-LS ≥13, 58% were receiving 
these medications, with 14.1%, 46.3%, and 
21.4% receiving tricyclic antidepressants, selective 
serotonin reuptake inhibitors (SSRIs) or other 
nontricyclic antidepressants, or antipsychotics, 
respectively, indicating that for many patients, 
PBA symptoms were not sufficiently controlled 
by the medications prescribed (Table 3). 
DISCUSSION
This is the first epidemiologic survey to assess 
the prevalence of PBA symptoms of involuntary 
laughing and crying using a single methodology 
across the six conditions with which PBA is most 
commonly associated. The survey results suggest 
that the total mean prevalence of PBA across 
these disease populations ranges from about 
10%, when identified with either a PLACS score 
of ≥13 or a CNS-LS score of ≥21, to 37.5%, when 
identified by a CNS-LS score of ≥13 (Table 1). 
Depending on the specific scale and threshold 
score used to define PBA and the data source used 
to estimate the size of the US population afflicted 
with the six associated conditions, estimates of 
the PBA population range from a low of 0.55 
million to 1.9 million (PLACS≥13/CNS-LS≥21) to 
a high of 2.2 million to 7.1 million (CNS-LS≥13) 
US cases. Considering that PBA occurs in other 
neurological conditions besides the six surveyed 
here,3,5 and this survey did not systematically 
include institutionalized patients, the prevalence 
of PBA in the USA appears conservatively to be 
at least 0.5 million to 2 million.
This survey also showed that labile anger/
frustration is present in more than half of patients 
with these underlying neurological disorders, 
and is more common in patients who also 
have PBA symptoms of inappropriate laughing 
and crying (88.3% of patients with CNS-LS≥13 
Table 3. Medication use and percentage of patients with scores indicating pseudobulbar affect.
 CNS-LS≥13 CNS-LS≥21 PLACS≥13
Concomitant medications (n=857) (n=195) (n=217)
Any antidepressant or antipsychotic (n=922), % 58.0 69.6 72.7
Tricyclic antidepressants (n=185), % 14.1 27.8 35.1
Other antidepressants  (n=734), % 46.3 55.6 45.5
Antipsychotics (n=218), %   21.4 37.3 42.2
No antidepressant or antipsychotic medication (n=1396), %  42.0 30.4 27.3
CNS-LS=Center for Neurological Studies-Lability Scale; PLACS=Pathological Laughing and Crying Scale.
Adv Ther (2011) 28(7):586-601. 595
also scored ≥15 on the CNS-LS lability subscale 
compared with 41.3% of those with CNS-LS 
<13). These findings are consistent with previous 
epidemiological data suggesting that episodes 
of anger and frustration, in addition to laughter 
and crying, are an important component of 
emotional lability in PBA.4 In addition, the 
survey showed that recognition, diagnosis, and 
treatment of PBA are substantially suboptimal, 
with only about 40% of patients who discussed 
their episodes receiving a diagnosis (most often 
depression), and many patients remaining 
untreated or ineffectively treated. 
These prevalence findings concur with 
previous data showing wide variance in PBA 
prevalence among the commonly associated 
underlying neurological conditions (Table 1) 
and within individual disease populations 
depending on methodology for identifying PBA 
(Figure 15,10,11,15-32). Estimates of PBA prevalence 
in patients with ALS, for example, have ranged 
from 2% to 60%,15,17,20 with expert consensus 
opinion accepting the estimate of “as many 
as 50%”.16 Indeed, a 2009 study of treatment 
outcomes in 5600 ALS patients found that 42% 
of patients were receiving treatment for PBA.52
The present estimates of 27.5%, 32.5%, and 
50% PBA prevalence in ALS patients identified 
with the CNS-LS≥21, PLACS≥13, and CNS-LS≥13 
thresholds, respectively, are thus within the 
range of previously reported and clinically 
accepted estimates. 
In patients with AD, the reported prevalence 
of nonspecific emotional lability has ranged 
from about 25% to 74%.3,53,54 A study that 
identified PLC using a semi-structured interview 
based on Poeck’s criteria for diagnosis of PBA, 
which require that the episodes are provoked 
by nonspecific stimuli, are uncontrollable, and 
do not reflect the subjective affective state or 
influence the prevailing mood,55,56 found that 40 
(39%) of 103 patients with AD screened positive 
for PBA.22 Patients in this study were also given 
a comprehensive battery of psychological 
and cognitive tests (including the PLACS) 
to identify correlates of pathological affect. 
Respective PLACS scores were 0.0 and 1.8 in 
patients without pathological affect compared 
with 0.0 and 11.9 in patients diagnosed with 
pathological crying and 1.8 and 7.3 in patients 
diagnosed with mixed pathological affect. The 
prevalence of PBA in this trial is consistent with 
the estimate of 38.5% found in the present 
study using the CNS-LS≥13 threshold, and is 
about four times higher than both the 9.2% 
and 9.6% prevalence estimates using PLACS≥13 
and CNS-LS≥21, respectively. In MS patients, 
estimates of PBA prevalence have ranged from 
7% to 29%.21,24,25,57 Feinstein et al.,24 interviewed 
152 consecutive outpatients with MS and 
identified a point prevalence for PLC of 9.9% 
(15/152) using the Poeck criteria. Patients were 
also interviewed using the PLACS; however, 
mean PLACS scores are provided for only 11 of 
the patients diagnosed with PLC who went on 
to participate in a case-control study; the mean 
PLACS score in these patients was 17 (range 
10-23). The point prevalence in the study by 
Feinstein et al. was similar to that found for MS 
patients in our survey sample using a PLACS≥13 
cutoff (9.8%), or CNS-LS≥21 (9.8%), while the 
rate shown using the CNS-LS≥13 (46.2%) was 
over four times higher (Table 1). This disparity 
could be related to the more restrictive criteria 
of Poeck used by Feinstein et al., compared with 
the CNS-LS≥13 cutoff, and may thus illustrate 
how more exclusive criteria can better define 
specific characteristics of PBA, but may also 
underestimate the prevalence of patients with 
involuntary and uncontrollable laughing and/
or crying episodes, regardless of how they relate 
to context or inner mood. 
Reported PBA prevalence rates in PD patients 
are typically lower than those in patients with ALS, 
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dementia, and MS and have ranged from 5.1% 
to 16.8%.5,11,14,58 This survey also showed a lower 
prevalence of PBA in PD patients of 5% using 
the PLACS≥13 cutoff, while the CNS-LS≥21 
yielded a lower estimate of 3.6%, and the 
CNS-LS≥13 threshold derived a markedly higher 
estimate of 24% (Table 1). In studies that used 
criteria similar to this survey for the detection 
of PBA in PD patients, one (n=193) reported a 
PBA prevalence of 7%, based on the Cummings 
criteria, which require that PBA episodes cause 
clinically significant distress or impairment in 
social or occupational functioning.58,59 This 
study also found that CNS-LS cut-off scores 
of ≥13 and ≥17 yielded rates of 42.5% and 
16.6%, respectively, of patients with “clinically 
significant PBA symptoms.” Notably, a 
CNS-LS cutoff of ≥11 provided the maximum 
sensitivity (93%) and specificity (51%) when 
correlated with the Cummings criteria results. 
The inability to obtain both high sensitivity 
and specificity with the CNS-LS in this study 
would raise questions as to the validity of this 
scale in PD patients.58 However, another study 
in patients with movement disorders (n=269), 
which used a CNS-LS≥17 cutoff, reported a 7.1% 
prevalence of PBA in a subgroup of patients 
with PD (n=168), almost the same rate as found 
with the Cummings criteria.5 Therefore, both 
the 5% and 3.6% estimates based on PLACS≥13 
cutoff, and CNS-LS≥21, respectively, in this 
survey appear to be conservative and consistent 
with prevalence estimates obtained using 
structured interviews. 
Studies in stroke patients have reported 
prevalence of crying and laughing syndromes 
ranging from about 6% to 52%.9,12,27-30,60 None 
of these studies used the CNS-LS or the PLACS 
to identify PBA, although the PLACS has been 
validated in stroke patients, and a score of 
13 was found to identify patients with PBA 
(sensitivity=0.88, specificity=0.96, positive 
predictive value=0.83).31 Several used the “Kim 
criteria” for emotional incontinence, which 
require that the patient has shown excessive 
and/or inappropriate laughter or crying 
or both, as compared with the premorbid 
state, on at least two occasions.12,27,29,60
Three studies used the “House criteria” for 
emotionalism, described as tearfulness that is 
more frequent than before the stroke, sudden 
and uncontrollable, but without regard to 
appropriateness of the expression.9,29,30 In this 
survey, the PBA prevalence in stroke of 4.7% and 
4.3% found with the PLACS≥13 and CNS-LS≥21 
criteria, respectively, are below even the lowest 
rate previously found in stroke patients, while 
the rate of 27.6% found with the CNS-LS≥13 
cutoff is within the previously reported 
prevalence range identified in previous trials. 
Here again, in stroke patients as noted above 
for MS patients, it appears that the type or 
threshold of criteria used to define and identify 
PBA may result in significant differences in its 
estimated prevalence. This suggests that the 
choice of criteria for identification of PBA may 
rest, in part, with the purpose of the clinician 
or researcher, such as whether to maximize 
sensitivity in capturing patients experiencing 
uncontrollable laughing and crying episodes, 
perhaps for further evaluation, or place a greater 
emphasis on specificity in identifying a well-
defined population with distinct characteristics. 
For example, based on their CNS-LS validation 
studies, Moore and colleagues suggested that 
a cut-off score of 13 on this scale (sensitivity 
0.84, specificity 0.81) was most appropriate 
for general research purposes, while a less 
stringent CNS-LS cutoff of 11 (sensitivity 0.91, 
specificity 0.71) was considered appropriate for 
clinical screening of patients with troublesome 
laughing and/or crying episodes.4
Only two previous studies have reported 
PBA prevalence in TBI.10,32 In one study, 16 
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(5.3%) of 301 hospitalized patients with TBI 
were identified as having PBA based simply 
on whether the patients were observed by 
clinicians to laugh or cry excessively in response 
to minimal stimulation.32 The other study, 
which used criteria similar to that of Poeck to 
identify PBA, and the PLACS as a measure of PBA 
symptom severity, found that 10 of 92 (10.9%) 
hospitalized patients with TBI had PBA, and the 
mean (SD) PLACS score for these patients was 
13.6 (4.6).10 In comparison, the present survey 
found considerably higher PBA rates in TBI 
patients of 17.4% and 15.5% using PLACS≥13 
and CNS-LS≥21 thresholds, respectively, and 
48.2% with the CNS-LS≥13 cutoff. 
Overall, PBA prevalence in this survey, as 
estimated using PLACS≥13 and CNS-LS≥21 
thresholds, was consistent with or below 
that reported in other studies for five of the 
six individual disease populations surveyed 
(Figure 1). This survey found a higher PBA 
prevalence in TBI patients than previously 
reported; however, the previous data in this 
population are limited.10,32 The CNS-LS≥13 cutoff 
generally yielded PBA rates above those found in 
previous studies, but produced a result similar 
to what is probably the most reliable previous 
estimate in AD patients, while the PLACS≥13 
and CNS-LS≥21 results were well below that 
rate. These comparisons suggest that the total 
US prevalence estimates of approximately 
0.5–2 million, based on the PLACS≥13 and 
CNS-LS≥21 thresholds, obtained in this survey, 
may be conservative, while the estimate of about 
7 million based on the CNS-LS≥13 is probably 
high. 
The considerable prevalence of PBA identified 
by these survey results highlight the need for 
improved recognition, diagnosis, and treatment. 
However, less than half (41%) of survey 
participants who discussed their inappropriate 
laughing and crying episodes with a physician 
were given a diagnosis, and in no case was the 
reported diagnosis PBA (Figure 2). It has been 
noted that PBA episodes may at times resemble 
crying spells in depression61 and emotional 
lability in mania,62 partly explaining the 
difficulty in diagnosis. 
While this study also documented low rates 
of recognition and treatment of PBA, it should 
also be noted that no FDA-approved medications 
indicated for PBA were available until recently. 
Among medications reportedly used off-label 
for PBA,3,63 there is some evidence of efficacy for 
SSRIs64-66 and tricyclic antidepressants,1,31 while 
antipsychotics may be effective in treatment 
of emotional lability67 and anger/aggression.68
However, about half of surveyed patients 
registering PBA symptoms were already receiving 
antidepressant or antipsychotic medications, 
indicating that these treatments may not be 
optimally effective in some patients. 
Dextromethorphan/quinidine (Nuedexta™, 
Avanir Pharmaceuticals, USA), an uncompetitive 
N-methyl-d-aspartate receptor antagonist and 
sigma-1 receptor agonist,63 was approved by the 
FDA in 2010 as the first medication indicated for 
treatment of PBA.69 This agent has demonstrated 
efficacy in treating PBA in phase 3 clinical trials 
in patients with ALS or MS.33,36,70
Certain limitations of this study must be 
noted. It was undertaken on patients self-
reported as having been diagnosed with one of 
the chronic diseases, ALS, AD, MS, PD, or stroke, 
or identified by directed screening for TBI. The 
Harris Chronic Illness Panels are household-based 
and do not include institutionalized groups, 
which could bias towards a less severely affected 
population. To minimize such bias, caregivers 
were included as a proxy for more functionally 
impaired patients; however, the survey 
methodology may have resulted in recruitment 
of a less severely affected population leading to 
potential underestimation of the overall disease 
598 Adv Ther (2011) 28(7):586-601.
prevalence. The methodology used in this 
survey also limited the clinical details available 
for greater in-depth analysis of the prevalence 
results, and the amount of information available 
about the relationship of the specialty of the 
treating physician to diagnosis of PBA, which 
is of significance in regard to whether PBA was 
treated and how. Nevertheless, the methodology 
resulted in a large survey sample and produced 
important results and conclusions about PBA 
across the board in the USA, which could offer 
pointers to future in-depth studies that are 
needed.
In conclusion, this survey estimated the 
mean prevalence of PBA to be at least 10% 
and up to 38%, depending on the symptom 
threshold used for detection, across the six most 
common underlying neurological conditions 
associated with PBA. Based on US population 
estimates for these neurologic conditions, these 
survey data indicate a total US PBA prevalence 
of up to approximately 2 million people using a 
high symptom threshold to as high as 7 million 
using a lower symptom threshold. These data 
also highlight the need for greater awareness, 
recognition, and treatment of PBA. Additional 
studies are warranted to confirm the validity and 
reliability of the PLACS and CNS-LS, including 
the CNS-LS anger/frustration subscale, in all the 
most common underlying conditions associated 
with PBA and, perhaps, to refine these diagnostic 
criteria. 
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